Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

Summary by AI BETAClose X

Novo Nordisk announced that the CHMP has recommended Wegovy® pill (oral semaglutide) for approval in the EU as the first oral GLP-1 treatment for weight management, demonstrating a mean weight loss of 16.6% and reducing the risk of major adverse cardiovascular events. This oral therapy, which has no drug-drug restrictions, achieved weight loss comparable to injectable Wegovy® and is planned for launch in select markets outside the US in the second half of 2026.

Disclaimer*

UK 100

Latest directors dealings